BioSpace News Archive

Business

Tessera Cuts Dozens of Jobs Following Positive Preclinical Results

The genetic engineering startup, recently honored by BioSpace readers for its work environment, is downsizing as it seeks to launch its first clinical trials.

April 26, 2024
·
1 min read
·
Neil Versel
Drug Development

What’s Next for Obesity Therapeutics? Higher Quality Weight Loss

With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore treatments that preserve muscle mass as patients shed pounds.

April 26, 2024
·
5 min read
·
Kate Goodwin
FDA

Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty

Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.

April 26, 2024
·
2 min read
·
Tristan Manalac
Drug Delivery

Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost

Starting in June 2024, Evernorth Health Services will offer Humira biosimilar products with no out-of-pocket cost through its Accredo specialty pharmacy.

April 26, 2024
·
2 min read
·
Tristan Manalac
Business

Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline

Gilead on Thursday reported revenue growth in the first quarter of 2024, driven by the strong sales of its HIV, cancer and liver diseases franchises, while culling a number of candidates.

April 26, 2024
·
2 min read
·
Tristan Manalac
Business

BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree

Is there a connection between Bristol Myers Squibb’s announcement that it will reduce its headcount by 6% and the company’s recent acquisitions of Karuna, Mirati and RayzeBio?

April 26, 2024
·
2 min read
·
Greg Slabodkin
Policy

GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement

With its lawsuit filed against Pfizer and BioNTech, the British multinational biopharma has joined the high-profile patent battle over mRNA technology used in COVID-19 vaccines.

April 26, 2024
·
2 min read
·
Tristan Manalac
Business

AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq

Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.

April 26, 2024
·
2 min read
·
Tyler Patchen
Business

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets.

April 26, 2024
·
5 min read
Biotech Bay

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo® in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

April 26, 2024
·
46 min read